Medpace (MEDP) Expected to Announce Quarterly Earnings on Monday

Medpace (NASDAQ:MEDP - Get Free Report) will likely be announcing its Q2 2025 earnings results after the market closes on Monday, July 21st. Analysts expect the company to announce earnings of $3.01 per share and revenue of $537.70 million for the quarter. Medpace has set its FY 2025 guidance at 12.260-13.040 EPS.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.06 by $0.61. The company had revenue of $558.57 million for the quarter, compared to analysts' expectations of $528.38 million. Medpace had a return on equity of 54.36% and a net margin of 19.31%. During the same period last year, the firm earned $3.20 earnings per share. On average, analysts expect Medpace to post $12 EPS for the current fiscal year and $14 EPS for the next fiscal year.

Medpace Trading Down 1.0%

Medpace stock traded down $3.14 during trading hours on Monday, hitting $320.36. 352,586 shares of the stock traded hands, compared to its average volume of 413,640. The firm's 50-day moving average price is $305.61 and its two-hundred day moving average price is $318.52. The company has a market cap of $9.21 billion, a PE ratio of 24.45, a PEG ratio of 5.85 and a beta of 1.47. Medpace has a one year low of $250.05 and a one year high of $459.77.

Analyst Upgrades and Downgrades

Several analysts have weighed in on MEDP shares. Leerink Partnrs raised Medpace to a "hold" rating in a research report on Monday, March 24th. Robert W. Baird cut their price objective on Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 23rd. Mizuho cut their price objective on Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Leerink Partners initiated coverage on Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 price objective on the stock. Finally, TD Cowen cut Medpace from a "buy" rating to a "hold" rating and dropped their price target for the stock from $370.00 to $328.00 in a research report on Monday, April 14th. Twelve equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $344.82.

Insider Transactions at Medpace

In related news, Director Fred B. Davenport, Jr. sold 1,712 shares of the company's stock in a transaction that occurred on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total value of $516,715.84. Following the transaction, the director directly owned 2,998 shares of the company's stock, valued at approximately $904,856.36. This represents a 36.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 20.30% of the company's stock.

Hedge Funds Weigh In On Medpace

Several hedge funds and other institutional investors have recently modified their holdings of MEDP. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Medpace by 3.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company's stock worth $24,929,000 after purchasing an additional 3,010 shares in the last quarter. NewEdge Advisors LLC increased its stake in shares of Medpace by 22.1% in the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company's stock worth $319,000 after purchasing an additional 190 shares in the last quarter. Finally, Geneos Wealth Management Inc. increased its stake in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after purchasing an additional 37 shares in the last quarter. 77.98% of the stock is owned by institutional investors.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.